Two thirds of the applications submitted for entry into the European Medicines Agency's new PRIME (priority medicines) scheme in the first month after its launch were missing a pediatric investigation plan or a PIP waiver.
Many PRIME Applicants Are Missing Pediatric Investigation Plans
Aside from pediatrics research issue, most of the first batch of applications for the new priority review scheme were "in scope," with numerous therapeutic areas targeted.